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Abstract
Background: Aberrant activation of the Hedgehog (Hh) pathway is a key driver in the pathogenesis of basal cell
carcinomas (BCCs), including patients with BCC nevus syndrome (BCCNS). It is unclear whether BCCs arising in
patients with BCCNS respond differently to vismodegib than in patients without BCCNS. We examined the best
overall response rate (BORR) and adverse events (AEs) of vismodegib in patients with advanced BCC (aBCC) with
and without BCCNS.
Methods: Patients were treated with vismodegib 150 mg/day in the ERIVANCE BCC trial (ClinicalTrials.gov number,
NCT00833417) and the expanded access study (EAS; ClinicalTrials.gov number, NCT01160250). BCCNS diagnosis was
based on medical history at the time of enrollment. Metastatic BCC response was evaluated using Response
Evaluation Criteria In Solid Tumors, version 1.0 (RECIST v1.0) in both studies. Locally advanced BCC was evaluated by
a novel composite end point in ERIVANCE BCC and by RECIST v1.0 in the EAS. Response assessments were
performed every 8 weeks in ERIVANCE BCC and every 8–16 weeks in the EAS. Safety assessments (National Cancer
Institute Common Terminology Criteria for Adverse Events, version 3.0) were performed monthly in both trials.
Because of described differences in response assessment/schedule, patients with BCCNS were not pooled across
trials. Analytic cohorts for BCCNS and sporadic aBCC were created within each trial for comparison using descriptive
statistical methods.
Results: Forty-one patients with BCCNS were included in the study: 22 from ERIVANCE BCC and 19 from the EAS.
Investigator-assessed BORR in BCCNS groups ranged from 31 to 81 % in patients with locally advanced BCC (n = 33)
and was 50 % in patients with metastatic BCC (n = 6). These results were comparable with the non-BCCNS groups.
Incidence and severity of AEs were also comparable between the BCCNS and non-BCCNS groups. Amenorrhea was
observed in both patient cohorts and was reversible in two patients who discontinued treatment.
Conclusion: Vismodegib demonstrated comparable efficacy and safety against aBCC in patients with and without
BCCNS.
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Background
First described in patients with basal cell carcinoma
(BCC) nevus syndrome (BCCNS), aberrant activation of
the Hedgehog (Hh) pathway is a key pathogenic driver
in BCC [1, 2]. The majority of genetic alterations in the
Hh pathway are loss-of-function mutations in the
tumor-suppressor gene PTCH1 [2, 3]. Patients with
BCCNS develop dozens of BCCs over their lifetimes [4],
including unresectable advanced BCCs (aBCCs) that are
either locally advanced (laBCC) or metastatic (mBCC).
Therapeutic options are limited for patients with
aBCC. Vismodegib, the first Hh pathway inhibitor (HPI)
approved by the US Food and Drug Administration
(FDA), is indicated for patients who have aBCC that has
recurred after surgery or who are not candidates for
surgery and radiation [5]. In its pivotal approval study
(ERIVANCE BCC), vismodegib demonstrated an overall
response rate (ORR) of 43 % in patients with laBCC and
30 % in patients with mBCC by independent review [5].
In addition, vismodegib reduced the size of existing BCC
lesions and prevented development of new lesions com-
pared with placebo in 41 patients with BCCNS with
multiple surgically eligible BCCs who were enrolled in
an investigator-sponsored trial [6].
It is unclear whether BCCs arising in patients with
BCCNS respond differently to vismodegib than in pa-
tients without BCCNS. Here, we investigate the efficacy
and safety of vismodegib in patients with aBCC with and
without BCCNS enrolled in the ERIVANCE BCC pivotal
trial [5] and the US expanded access study (EAS) [7].
Methods
Study design and treatment
This was a pooled analysis of two similar open-label
clinical trials. ERIVANCE BCC (ClinicalTrials.gov number,
NCT00833417) was an international, multicenter, non-
comparative phase 2 study. EAS (ClinicalTrials.gov num-
ber, NCT01160250) was a multicenter, open-label,
noncomparative expanded access study to provide patients
with aBCC access to vismodegib prior to regulatory
approval, and was terminated early due to FDA ap-
proval. Patients received oral vismodegib 150 mg/day
until disease progression, intolerable toxicity, patient
withdrawal, or study termination. All patients signed
written informed consent.
Key eligibility criteria
Key eligibility criteria for the ERIVANCE BCC and EAS
studies were similar. Patients with mBCC had histologic
confirmation of distant metastasis. Patients with laBCC
had ≥1 lesion measuring ≥10 mm, inoperable or surgery
contraindicated, and prior radiation to ≥1 lesion, unless
contraindicated or inappropriate. Other criteria included
age ≥18 years, adequate organ function, and Eastern
Cooperative Oncology Group performance status ≤2.
Both trials used Response Evaluation Criteria In Solid
Tumors, version 1.0 (RECIST v1.0) for assessment of
mBCC and allowed enrollment of patients with BCCNS
as long as all other eligibility criteria were met. The EAS
also used RECIST v1.0 for assessment of patients with
laBCC. ERIVANCE BCC defined response as a ≥30 %
decrease in the externally visible or radiographic dimen-
sion (if applicable) or complete resolution of ulceration
(if present at baseline). BCCNS diagnosis was based on
medical history at the time of enrollment and/or assess-
ment of clinical investigator.
Assessments
Efficacy assessments
Response assessments were performed every 8 weeks in
ERIVANCE BCC and every 8–16 weeks in the EAS.
Safety assessments
Adverse events (AEs) were assessed on a monthly basis
in both trials and graded according to National Cancer
Institute Common Terminology Criteria for Adverse
events, version 3.0.
Analysis
All patient data available as of November 26, 2010 for
ERIVANCE BCC (primary analysis) and April 23, 2012
for US EAS (final analysis) were included in the analyses.
Analytic cohorts for BCCNS and non-BCCNS were cre-
ated within each trial for comparison using descriptive
statistical methods.
Data were not pooled across the trials because of the
described differences in the schedule and the criteria for
assessment of response. Best ORR (BORR) was analyzed
in efficacy-evaluable patients. Clopper-Pearson 95 %
confidence intervals (CIs) were computed.
Results
Patient characteristics
The ERIVANCE BCC trial enrolled 104 patients: 71
(68 %) with laBCC and 33 (32 %) with mBCC. Twenty-
two (31 %) patients with BCCNS had laBCC; no patients
with BCCNS had mBCC (Table 1). The EAS study en-
rolled 119 patients: 62 (52 %) with laBCC and 57 (48 %)
with mBCC. Twelve (17 %) patients with BCCNS had
laBCC; 7 (12 %) patients with BCCNS had mBCC. Base-
line demographic and disease characteristics were gener-
ally comparable between patients with and without
BCCNS, except for younger age and higher number of
women of childbearing potential (WCBP) in the BCCNS
cohort.
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Treatment exposure
Median duration of treatment with vismodegib was
shorter in the EAS study (5.0–7.1 months across cohorts)
than in the ERIVANCE BCC study (9.6–10.5 months
across cohorts). Within each trial, the median treatment
duration in patients with BCCNS was similar to the dur-
ation in patients without BCCNS. Median dose intensity
was similar (>97 %) across all cohorts in both studies.
Best overall response rate
Similar clinical activity was observed across all cohorts
in both studies. In the ERIVANCE BCC study, the
investigator-assessed BORR in patients with BCCNS
with laBCC was 81 % (95 % CI: 58–95 %); in those with-
out BCCNS, the BORR was 50 % (95 % CI: 34–66 %).
Although this study suggested that patients with BCCNS
with laBCC might be more responsive to vismodegib
than patients without BCCNS, this pattern was not ob-
served in the EAS, in which the BORR was 33 % (95 %
CI: 10–65 %) in patients with BCCNS and 50 % (95 %
CI: 35–65 %) in patients without BCCNS (Table 2).
Among patients with mBCC, the BORR was 46 %
(95 % CI: 28–64 %) in patients without BCCNS in the
ERIVANCE BCC study; no mBCC was noted in patients
Table 1 Patient demographics and baseline disease characteristicsa
Erivance BCC (N = 104) EAS (N = 119)















Median age, years (range) 47 (21–71) 67 (38–101) 62 (38–92) 52 (26–79) 67 (40–92) 58 (37–71) 63 (24–100)
Female, n (%) 10 (45) 22 (45) 9 (27) 6 (50) 13 (26) 3 (43) 9 (18)
WCBP, n (%) 3 (33) 1 (2) 2 (6) 4 (33) 2 (4) 1 (14) 1 (2)
ECOG PS, n (%)
0–1 22 (100) 44 (90) 32 (97) 12 (100) 46 (92) 7 (100) 45 (90)
2 0 5 (10) 1 (3) 0 4 (8) 0 5 (10)
Target lesions, n (%)
1 13 (59) 35 (71) 9 (27) 4 (33) 30 (60) 4 (57) 20 (40)
2 4 (18) 8 (16) 4 (12) 2 (17) 11 (22) 0 10 (20)
≥3 5 (23) 6 (12) 20 (61) 6 (50) 9 (18) 3 (43) 20 (40)
Prior treatment, n (%)
Surgery 21 (96) 41 (84) 32 (97) 12 (100) 45 (90) 7 (100) 47 (94)
Radiotherapy 1 (5) 21 (43) 19 (58) 1 (8) 19 (38) 2 (29) 33 (66)
Systemic therapy 5 (23) 3 (6) 10 (30) 2 (17) 9 (18) 2 (29) 18 (36)
Surgery contraindicated, n (%) 18 (82) 25 (51) NA 7 (58) 28 (56) NA NA
BCCNS basal cell carcinoma nevus syndrome, EAS expanded access study, ECOG PS Eastern Cooperative Oncology Group performance status, laBCC locally
advanced basal cell carcinoma, mBCC metastatic basal cell carcinoma, NA not available, WCBP women of childbearing potential
aThere were no patients with BCCNS with mBCC in the ERIVANCE BCC study; therefore, this column is omitted in the table
Table 2 Investigator-assessed BORR (efficacy-evaluable patients) comparing BCCNS and non-BCCNS patient groups
Erivance BCC (N = 96) EAS (N = 95)































Complete response 8 (38) 12 (29) 0 1 (8) 5 (11) 2 (33) 0
Partial response 9 (43) 9 (21) 15 (46) 3 (25) 17 (39) 1 (17) 9 (27)
Stable disease 3 (14) 12 (29) 15 (46) 6 (50) 21 (48) 3 (50) 17 (52)
Progressive disease 1 (5) 5 (12) 2 (6) 2 (17) 0 0 3 (9)
Not evaluable or missing 0 4 (10) 1 (3) 2 (17) 1 (2) 0 4 (12)
BCCNS basal cell carcinoma nevus syndrome, BORR best overall response rate, CI confidence interval, EAS expanded access study, laBCC locally advanced basal cell
carcinoma, mBCC metastatic basal cell carcinoma
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with BCCNS. In the EAS, patients with BCCNS with
mBCC had a BORR of 50 % (95 % CI: 12–88 %) and
those without BCCNS had a BORR of 27 % (95 % CI:
13–46 %).
Safety
No consistent trends in the incidence of AEs were ob-
served across studies. The most frequent AEs in patients
with BCCNS were alopecia (86 and 58 % in ERIVANCE
BCC and the EAS, respectively), muscle spasms (77 and
63 %), weight decrease (68 and 5 %), and dysgeusia (59
and 74 %) (Table 3). The most frequent AEs in patients
with non-BCCNS aBCC were alopecia (57 and 58 % in
ERIVANCE BCC and the EAS, respectively), muscle
spasms (66 and 72 %), weight decrease (40 and 18 %),
and dysgeusia (49 and 70 %) (Table 3). The longer period
of follow-up for ERIVANCE BCC compared with the
EAS likely accounts for differences in later-onset AEs
such as weight decrease. In both studies, there were
lower percentages of dysgeusia in patients with BCCNS
compared with patients without BCCNS. Incidences of
grade 3–5 AEs were 41 % in the BCCNS group versus
43 % in the non-BCCNS group in ERIVANCE BCC, and
16 % versus 32 % in the EAS.
For WCBP, amenorrhea or irregular menstruation was
reported in 2/3 (67 %) and 0/3 patients with and without
BCCNS, respectively, in the ERIVANCE BCC study. It
was reported in 2/5 (40 %) and 2/3 (67 %) patients with
and without BCCNS, respectively, in the EAS.
Discussion
Vismodegib demonstrated clinical activity across all co-
horts, including patients with BCCNS, confirming the
efficacy of HPIs in these patients [2, 3]. While numerical
differences in BORR were observed across cohorts, they
were not consistent trends that were clinically signifi-
cant. Rather, differences were likely due to similar but
nonidentical response criteria, treatment duration, and
length of follow-up in each study, as well as biologic fac-
tors that may affect treatment response (e.g., tumoral
heterogeneity, presence of SUFU mutation).
Numerical differences were also observed between co-
horts with respect to the incidence of various AEs; how-
ever, no consistent patterns were observed across the two
studies. As patients with BCCNS tend to be younger than
those without BCCNS, BCCNS cohorts also tend to
include a higher proportion of WCBP than non-BCCNS
cohorts. A survey of six phase 1 and 2 Roche-sponsored
studies of vismodegib that included WCBP determined
that irregular menses or amenorrhea occurred in 10
(28.5 %) of 35 premenopausal women (inclusive of the
women presented in this analysis), eight of whom had
BCCNS [8]. An analysis by BCCNS status was not per-
formed. Results of hormonal evaluation were available for
four patients after the onset of irregular menses or amen-
orrhea; two had normal values (premenopausal), one pa-
tient was considered postmenopausal, and one had
elevated follicle-stimulating hormone, elevated luteinizing
hormone, and normal estradiol values [8]. Menses re-
sumed in two patients who discontinued vismodegib, sug-
gesting that amenorrhea observed with vismodegib
treatment might be reversible.
When stratified for BCCNS status in this analysis,
amenorrhea was observed in WCBP in both groups. The
mechanism responsible has yet to be fully elucidated,
although the Hh pathway is known to play a role in fol-
licular development and patients with BCCNS frequently
develop ovarian cysts (25–50 % of patients) [4, 9].
Additionally, a recent case report suggested that vis-
modegib might induce amenorrhea by blockading
follicle-stimulating hormone receptor-dependent signal
transduction [10].
Conclusions
Vismodegib demonstrates clinical activity in patients
with aBCC with and without BCCNS. Overall, the safety
profile was similar in both groups, an important consid-
eration when counseling patients.
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Any AE 22 (100) 82 (100) 18 (95) 98 (98)
Grade 3–5 AE 9 (41) 35 (43) 3 (16) 32 (32)
Alopecia 19 (86) 47 (57) 11 (58) 58 (58)
Muscle spasms 17 (77) 54 (66) 12 (63) 72 (72)
Weight decreased 15 (68) 33 (40) 1 (5) 18 (18)
Dysgeusia 13 (59) 40 (49) 14 (74) 70 (70)
Nausea 9 (41) 21 (26) 3 (16) 20 (20)
Fatigue 8 (36) 29 (35) 7 (37) 16 (16)
Diarrhea 7 (32) 16 (20) 3 (16) 27 (27)
Arthralgia 5 (23) 11 (13) 2 (11) 2 (2)
AE adverse event, BCCNS basal cell carcinoma nevus syndrome, EAS expanded
access study
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